Rhythm Biotherapeutics Inc.

Profile

Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation. Its patented GMP process produces natural vesicles enriched with anti-inflammatory and anti-fibrotic cargo. Supported by strong preclinical efficacy in large-animal models, it is advancing toward regulatory submission for a Phase 1 trial in 2026. Its technology addresses a major unmet need, offering safer, targeted prevention of post-operative atrial fibrillation with potential expansion into broader arrhythmia and cardiovascular indications.

Website

rthm.bio

Contact


Event details

Date: November 9 - 11, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

<?php global $lang_id; switch ($lang_id) { case "fr": echo 'Total de 24'; break; case "pt-br": echo 'Total de 24'; break; case "es": echo 'Total de 24'; break; case "ja": echo '24 合計'; break; case "ko": echo '24 총계'; break; case "en": default: echo '24 in total'; break; } ?>